CombiMatrix gains $2.2m US funding:
This article was originally published in Clinica
Executive Summary
The US Department of Defense (DoD) has awarded a one-year, $2.2m contract to CombiMatrix to fund the further development of its microarrays for a multipathogen- and chemical-detection system, using its "on chip" electrochemical detection process. The Newport Beach, California company has demonstrated that its products can simultaneously detect toxins, viruses and bacteria using its semiconductor-based microarrays, under previously DoD-funded research programmes. These systems are currently in use at several military and government laboratories as well as civilian installations.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.